Revelation Biosciences director awarded 32K shares

REVELATION BIOSCIENCES, INC.

Rhea-AI Filing Summary

REVELATION BIOSCIENCES, INC. (REVB) reported that director Lakhmir S. Chawla acquired 32,011 shares of common stock on August 17, 2026 via a restricted stock award granted at $0.00 per share under the company’s 2021 Equity Incentive Plan. Following this grant, Chawla holds 44,169 shares directly. The award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, subject to continued service, with potential acceleration upon certain performance milestones.

Insider Trade Summary

Grant/Award: 32,011 shares

Grant/Award 1 txn

Insider Chawla Lakhmir S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	32,011	$0.00	$0.00

Holdings After Transaction: Common Stock — 44,169 shares (Direct)

Footnotes (1)

1. F1. These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

Key Figures

Restricted stock award: 32,011 shares Award price per share: $0.00 per share Shares owned after transaction: 44,169 shares +2 more

5 metrics

Restricted stock award 32,011 shares Common Stock granted to director on August 17, 2026

Award price per share $0.00 per share Reported transaction price for the restricted stock award

Shares owned after transaction 44,169 shares Total direct holdings of Lakhmir S. Chawla following the award

Initial vesting tranche 50% Shares vesting on the two-year anniversary of the grant date

Final vesting tranche 50% Shares vesting on the four-year anniversary of the grant date

Key Terms

restricted stock award, vesting, Equity Incentive Plan, performance milestones

4 terms

restricted stock award financial

"These shares are subject to a restricted stock award granted under the Revelation"

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

vesting financial

"with 50% of the shares vesting on the two-year anniversary of the grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Equity Incentive Plan financial

"restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

performance milestones financial

"such vesting could be accelerated upon the achievement of certain performance milestones"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did REVB disclose for Lakhmir S. Chawla?

REVB disclosed that director Lakhmir S. Chawla received a grant of 32,011 restricted shares of common stock on August 17, 2026 at $0.00 per share, under the company’s 2021 Equity Incentive Plan.

How many REVB shares does Lakhmir S. Chawla own after this Form 4 transaction?

After the reported grant, Lakhmir S. Chawla directly owns 44,169 shares of REVB common stock. This figure reflects his holdings following the restricted stock award reported in the Form 4.

What are the vesting terms of the 32,011-share restricted stock award at REVB?

The 32,011-share restricted stock award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, contingent on continued service, with potential acceleration upon achieving specified performance milestones.

Was the REVB restricted stock award to Lakhmir S. Chawla a market purchase or a grant?

It was a grant/award acquisition, not a market purchase. The Form 4 classifies the transaction with code A, indicating a grant or award of 32,011 restricted shares at a reported price of $0.00 per share.

Is the REVB Form 4 transaction for Lakhmir S. Chawla under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox as false, meaning the transaction is not affirmed as made under a Rule 10b5-1 trading plan based on the document-level status provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:01 PM Accepted by SEC EDGAR 08/18/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chawla Lakhmir S

(Last) (First) (Middle)

4660 LA JOLLA VILLAGE DR

SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		A		32,011(1)	A	$0	44,169	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

	/s/ J.P. Galda, as attorney-in-fact for Lakhmir S Chawla	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)